PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 8 Issue 3

Psoriasis: White Paper

Christina Rahm*

September 02, 2026

View PDF

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disorder characterized by dysregulation of the immune system and aberrant keratinocyte proliferation. In this condition, immune cells mistakenly identify healthy skin cells as pathogenic, triggering a sustained inflammatory response. This immune activation accelerates the epidermal life cycle, resulting in excessive keratinocyte turnover, erythema, and the accumulation of thick, pruritic, scaly plaques (Chakith M. R. et al., 2025). At the molecular level, psoriasis is largely driven by dysregulation of the TNF-α / IL-23 / IL-17 axis. Elevated levels of TNF-α, IL-23, and IL-17 promote inflammatory signaling and stimulate rapid skin cell proliferation, contributing to plaque formation (Sieminska et al., 2024; Gao et al., 2025). IL-23 plays a pivotal upstream role by promoting the release of IL-17A and IL-22 from Th17 cells, amplifying downstream cytokine cascades and perpetuating a self-sustaining inflammatory cycle that is often difficult to interrupt (Sieminska et al., 2024).

Importantly, psoriasis is increasingly recognized as a systemic inflammatory condition rather than solely a dermatologic disorder. Many patients experience comorbidities including psoriatic arthritis, metabolic and endocrine dysfunction, cardiovascular complications, and elevated rates of depression (Chularojanamontri, 2025). Although biologic therapies targeting TNF-α and the IL-23/IL-17 pathway have demonstrated significant efficacy, they are often associated with high cost, long-term immune suppression, and variable durability of response (ten Bergen et al., 2020). These limitations have renewed interest in integrative approaches that aim to modulate inflammatory signaling while supporting skin barrier repair and systemic balance. This paper explores a mechanistically grounded therapeutic strategy incorporating zeolite extract, curcumin, resveratrol, and aloe vera. The proposed model aligns with known inflammatory pathways, oxidative stress mechanisms, and emerging insights into the gut–skin axis. Recent clinical findings further support the biological plausibility of targeting immune modulation, redox balance, and barrier integrity as complementary strategies in psoriasis management.

References

  1. Amalia N., et al. “The gut-skin axis in psoriasis: Evidence-based insights from a meta-analysis on probiotics-synbiotics-mediated microbiota interventions”. Medicine in Microecology 25 (2025): 100126.
  2. Antiga E., et al. “Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris”. BioMed Research International 2015 (2015): 283634.
  3. Armstrong AW and Read C. “Pathophysiology, clinical presentation, and treatment of psoriasis: A review”. JAMA 323.19 (2020): 1945-1960.
  4. Buhaș MC., et al. “Gut Microbiota in Psoriasis”. Nutrients 14.14 (2022): 2970.
  5. Chakith MR., et al. “Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches”. PeerJ 13 (2025): e19325.
  6. Chen L., et al. “Skin and Gut Microbiome in Psoriasis: Gaining Insight into the Pathophysiology of Psoriasis and Finding Novel Therapeutic Strategies”. Frontiers in Microbiology 11 (2020): 589726.
  7. Chiricozzi A., et al. “Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis”. Journal of Investigative Dermatology 131.3 (2011): 677-687.
  8. Choonhakarn C., et al. “A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis”. Journal of the European Academy of Dermatology and Venereology 24.2 (2010): 168-172.
  9. Chularojanamontri L., et al. “A practical guide to biologic treatments for psoriasis in resource-limited areas”. Asian Pacific Journal of Allergy and Immunology 43.3 (2025): 410-421.
  10. Dring JC., et al. “Review of Applications of Zeolites in Dermatology: Molecular Perspectives and Translational Potentials”. International Journal of Molecular Sciences 26.14 (2025): 6821.
  11. Gao Y., et al. “Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research”. Pharmaceutics 17.1 (2025): 56.
  12. Hawkes JE., et al. “Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis”. Journal of Immunology 201.6 (2018): 1605-1613.
  13. Kantasa T., et al. “Therapeutic Potential of Curcumin and Novel Formulations in Psoriasis Treatment: Evidence and Future Prospects”. Drug Design Development and Therapy 19 (2025): 5387-5414.
  14. Lorenzo RD., et al. “Clinical Studies on Topical Curcumin”. Skin Pharmacology and Physiology (2023): 1-14.
  15. Lowe NJ., et al. “Immunology of Psoriasis”. Annual Review of Immunology 32.1 (2014): 227-255.
  16. Miroddi M., et al. “Review of Clinical Pharmacology of Aloe vera L. in the Treatment of Psoriasis”. Phytotherapy Research 29.5 (2015): 648-655.
  17. Sieminska I., et al. “The Immunology of Psoriasis-Current Concepts in Pathogenesis”. Clinical Reviews in Allergy & Immunology 66 (2024).
  18. Sikora M., et al. “Gut Microbiome in Psoriasis: An Updated Review”. Pathogens 9.6 (2020): 463.
  19. Smirnova M., et al. “Pharmacophore-Based Discovery of Substrates of a Novel Drug/Proton-Antiporter in the Human Brain Endothelial hCMEC/D3 Cell Line”. Pharmaceutics 14.2 (2022): 255.
  20. ten Bergen LL., et al. “The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment”. Scandinavian Journal of Immunology 92.4 (2020).
  21. Thye AYK., et al. “Gut-Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis”. Biomedicines 10.5 (2022): 1037.
  22. Zhang S., et al. “Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms”. Frontiers in Pharmacology 13 (2022): 903160.